JP2020002172A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020002172A5 JP2020002172A5 JP2019167098A JP2019167098A JP2020002172A5 JP 2020002172 A5 JP2020002172 A5 JP 2020002172A5 JP 2019167098 A JP2019167098 A JP 2019167098A JP 2019167098 A JP2019167098 A JP 2019167098A JP 2020002172 A5 JP2020002172 A5 JP 2020002172A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- monoclonal antibody
- seq
- administered
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562232343P | 2015-09-24 | 2015-09-24 | |
| US62/232,343 | 2015-09-24 | ||
| US201662375825P | 2016-08-16 | 2016-08-16 | |
| US62/375,825 | 2016-08-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515658A Division JP2018532728A (ja) | 2015-09-24 | 2016-09-23 | （持続性）外傷後頭痛の予防、治療および低減 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020002172A JP2020002172A (ja) | 2020-01-09 |
| JP2020002172A5 true JP2020002172A5 (2) | 2020-09-10 |
Family
ID=57121460
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515658A Pending JP2018532728A (ja) | 2015-09-24 | 2016-09-23 | （持続性）外傷後頭痛の予防、治療および低減 |
| JP2019167098A Pending JP2020002172A (ja) | 2015-09-24 | 2019-09-13 | （持続性）外傷後頭痛の予防、治療および低減 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515658A Pending JP2018532728A (ja) | 2015-09-24 | 2016-09-23 | （持続性）外傷後頭痛の予防、治療および低減 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20170088612A1 (2) |
| EP (1) | EP3353202B1 (2) |
| JP (2) | JP2018532728A (2) |
| KR (2) | KR20200035163A (2) |
| CN (1) | CN108473560A (2) |
| AU (2) | AU2016325738A1 (2) |
| CA (1) | CA2999809A1 (2) |
| EA (1) | EA201890578A1 (2) |
| ES (1) | ES2846878T3 (2) |
| HK (1) | HK1258385A1 (2) |
| IL (1) | IL258008A (2) |
| MX (1) | MX2018003713A (2) |
| WO (1) | WO2017051385A1 (2) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107827982B (zh) | 2011-05-20 | 2021-07-06 | H.伦德贝克公司 | 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途 |
| PE20141787A1 (es) | 2011-05-20 | 2014-12-07 | Alderbio Holdings Llc | Composiciones anti-cgrp y uso de las mismas |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| RU2019123406A (ru) | 2014-02-05 | 2019-10-03 | Мерк Шарп И Доум Корп. | Технология приготовления таблеток для cgrp-активных соединений |
| AU2015230933B2 (en) | 2014-03-21 | 2020-08-13 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| CN109952314A (zh) | 2016-09-23 | 2019-06-28 | 泰瓦制药国际有限公司 | 治疗难治性偏头痛 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US10899826B1 (en) | 2018-09-13 | 2021-01-26 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for an anti-CGRP antagonist antibody |
| WO2020146527A1 (en) * | 2019-01-08 | 2020-07-16 | Alder Biopharmaceuticals, Inc. | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
| AU2020259461A1 (en) * | 2019-04-18 | 2021-11-11 | Allergan Sales, Llc | CGRP antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
| CA3077973A1 (en) | 2020-04-06 | 2021-10-06 | H. Lundbeck A/S | Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies |
| JP2023528453A (ja) | 2020-06-03 | 2023-07-04 | ミオトックス，エルエルシー | 片頭痛障害を治療するためのゾーンおよび標的化方法および使用 |
| CN116390712A (zh) | 2020-07-29 | 2023-07-04 | 阿勒根制药国际有限公司 | 治疗偏头痛 |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| EP4408418A1 (en) | 2021-09-27 | 2024-08-07 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9704770D0 (sv) * | 1997-12-19 | 1997-12-19 | Astra Ab | New use |
| EP3069731A1 (en) * | 2005-11-14 | 2016-09-21 | Labrys Biologics Inc. | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| PE20141787A1 (es) * | 2011-05-20 | 2014-12-07 | Alderbio Holdings Llc | Composiciones anti-cgrp y uso de las mismas |
| BR112014016939A2 (pt) * | 2012-01-10 | 2019-09-24 | Noxxon Pharma Ag | ácidos nucleicos que se ligam especificamente a cgrp |
| US8722060B2 (en) * | 2012-05-23 | 2014-05-13 | William J. Binder | Method of treating vertigo |
-
2016
- 2016-09-23 MX MX2018003713A patent/MX2018003713A/es unknown
- 2016-09-23 EP EP16778888.4A patent/EP3353202B1/en active Active
- 2016-09-23 KR KR1020207008057A patent/KR20200035163A/ko not_active Withdrawn
- 2016-09-23 ES ES16778888T patent/ES2846878T3/es active Active
- 2016-09-23 AU AU2016325738A patent/AU2016325738A1/en not_active Abandoned
- 2016-09-23 HK HK19100783.0A patent/HK1258385A1/zh unknown
- 2016-09-23 CN CN201680068514.8A patent/CN108473560A/zh active Pending
- 2016-09-23 EA EA201890578A patent/EA201890578A1/ru unknown
- 2016-09-23 KR KR1020187011355A patent/KR20180058777A/ko not_active Ceased
- 2016-09-23 CA CA2999809A patent/CA2999809A1/en not_active Abandoned
- 2016-09-23 US US15/274,331 patent/US20170088612A1/en not_active Abandoned
- 2016-09-23 WO PCT/IB2016/055720 patent/WO2017051385A1/en not_active Ceased
- 2016-09-23 JP JP2018515658A patent/JP2018532728A/ja active Pending
-
2018
- 2018-03-11 IL IL258008A patent/IL258008A/en unknown
-
2019
- 2019-06-11 US US16/437,776 patent/US20200148761A1/en not_active Abandoned
- 2019-09-13 JP JP2019167098A patent/JP2020002172A/ja active Pending
- 2019-11-06 AU AU2019261726A patent/AU2019261726A1/en not_active Abandoned
-
2021
- 2021-04-05 US US17/222,737 patent/US20220048986A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020002172A5 (2) | ||
| JP2019530683A5 (2) | ||
| JP2008540447A5 (2) | ||
| JP2020503260A5 (2) | ||
| EP3201231B1 (en) | Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28 | |
| JP2014114288A5 (2) | ||
| JP2017510579A5 (2) | ||
| TW201024315A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide | |
| KR20120100914A (ko) | 에프라투주맙을 이용한 자가면역 및 염증 질환의 치료 | |
| JP2023524149A5 (2) | ||
| RU2019140933A (ru) | Средства, пути применения и способы лечения | |
| RU2017145662A (ru) | Моноклональные антитела и способы их применения | |
| JP2020527152A5 (2) | ||
| JP2018529635A5 (2) | ||
| JP2022531408A5 (2) | ||
| JP2020515577A5 (2) | ||
| JP2022512713A5 (2) | ||
| IL292706A (en) | Type i interferon inhibition in systemic lupus erythematosus | |
| JP2021502065A5 (2) | ||
| US20220213203A1 (en) | Dosing Regimens of Bispecific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies | |
| JP2025515092A5 (2) | ||
| EP4426347A1 (en) | Composition for treatment and prevention of covid-19 | |
| JP2022500382A5 (2) | ||
| US20250263472A1 (en) | Compositions and methods for treating and suppressing allergic responses | |
| EP4376885A1 (en) | Methods for treating acute myeloid leukemia with anti-ilt3 antibodies |